Skip NavigationSkip to Content
NCI HeaderNational Cancer InstituteU.S. National Institutes of Healthwww.cancer.gov

CBL Newsroom

December, 2012
photo of Dr. Kyung Lee
Former Burke Group Fellow Develops a New Cancer Drug Candidate and Expands to First Rate Global Program

Dr. Kyeong Lee, a former post-doctoral fellow in the Burke group, and now a pharmaceutical professor at Dongguk University in South Korea, in collaboration with researchers at KRIBB has developed a new anti-cancer drug candidate that regulates HIF-1α. A technology transfer agreement was signed with Ildong Pharmaceutical Co. Ltd in the fall of 2011 for further development into a broad-spectrum anticancer drug. In addition, Dr. Lee was chosen by the National Research Foundation of Korea as the lead researcher for the Open Translational Center for Innovative Drug (OTRCID). The focus of the OTRCID is to discover global level preclinical candidates to be used for further development. The Dongguk research team is expected to develop global anti-cancer drug candidates over the next 6 years.

For the full story, please look for the newsclippings (article #s 387169 and 11510362) on
the Dongguk University website at www.dongguk.edu/mbs/en/index.jsp

Home | Contact Us | Policies | Accessibility | Viewing Files | Search | CCR - For Our Staff

A service of the National Cancer Institute

National Cancer InstituteNational Institutes of HealthHealth and Human ServicesUSA Gov - Official Web Portal